The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

(2013) M. Baccarani et al.   BLOOD

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

(2013)   BLOOD

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

(2013) D. M. Ross et al.   BLOOD

Turkish Chronic Myeloid Leukemia Study: Retrospective Sectional Analysis of CML Patients

(2013) Fahri Sahin et al.   Turkish Journal of Hematology

Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

(2011) Carlo Gambacorti-Passerini et al.   JNCI-Journal of the National Cancer Institute

Response to the case report by Mattar: Generic Imatinib (Imatib, Cipla) in a patient with chronic myeloid leukemia in chronic phase

(2010) Jaideep Gogtay et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Failure of copy Imatib (CIPLA, India) to maintain hematologic and cytogenetic responses in chronic myeloid leukemia in chronic phase

(2010) Mervat Mattar   INTERNATIONAL JOURNAL OF HEMATOLOGY

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

(2010) François-Xavier Mahon et al.   LANCET ONCOLOGY

Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: A randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers

(2009) Susana Parrillo-Campiglia et al.   CLINICAL THERAPEUTICS